



Molecular drivers of Alzheimer's disease resilience through genomic and proteomic analyses

Timothy Hohman, PhD
Professor of Neurology
Vanderbilt University Medical Center


May 14, 2024

Computational Neurogenomics Team (CNT)

Faculty




Timothy Hohman
PhD




Logan Dumitrescu
MS, PhD



Derek Archer
PhD



Shannon Turner




Jane Zyski
MHA



Anna Lorenz
MSc



Jared Phillips



Ting-Chen Wang



Alex Contreras



Emma Nolan
MS

Staff Scientists and Staff Data Analysts



Abel Belachew
MS



Tonnar Castellano
MS



Michelle Clifton
MS




Alaina Durant



Vaibhav Janve
PhD




Alexis Smith
MS



Hui Shi, MS



Edward Miller
MIT



Aditi Sathe
MS



Julia Libby




Skylar Walters,
MS



Yiyang Wu
MD, PhD



Melissa Lara Gomez



Emily Mahoney




Dimitrios Zaras
PhD

Past Trainees



Rebecca Winfree
PhD



Mabel Seto
PhD




Jackie Eissman
PhD




Annah Scalfani
PhD




Precision Medicine in AD



Drug Discovery Framework in the Computational Neurogenomics Team



Explosion of Big Data in Alzheimer's Disease




Genomics

Molecular
Biomarkers

Structural
Brain Imaging



Cognition

Integrating AI into Genomic Discovery at NIA



New ADSP Programs

Maximum Score	Patient's Score	Questions
5		"What is the year? Season? Date? Day? Month?"
5		"Where are we now? State? County? Township? Hospital? Floor?"
3		The examiner names three unrelated objects clearly and slowly, then the instructor asks the patient to name all three of them. The patient's response is used for scoring. The examiner repeats them until patient names all of them, if possible.
5		"I would like you to count backward from 100 by sevens." (93, 86, 79, 72, 65, ...) Alternative: "Spell WORLD backwards." (D-L-R-O-W)
3		"Earlier I told you the names of three things. Can you tell me what those were?"
2		Show the patient two simple objects, such as a wristwatch and a pencil, and ask the patient to name them.
1		"Repeat the phrase: 'No ifs, ands, or buts.'"
3		"Take the paper in your right hand, fold it in half, and put it on the floor." (The examiner gives the patient a piece of blank paper.)
1		"Please read this and do what it says." (Written instruction is "Close your eyes.")
1		"Make up and write a sentence about anything." (This sentence must contain a noun and a verb.)
1		"Please copy this picture." (The examiner gives the patient a blank piece of paper and asks him/her to draw the symbol below. All 10 angles must be present and two must intersect.)



NCRAD

National Cell Repository for AD

NACC

National Alzheimer's Coordinating Center



LONI


Laboratory of Neuro Imaging



SCAN

Coordination

Data Integration



ADSP Cohort Studies

PHENOTYPES

IMAGES

GENOMICS

Receive Data

NIAGADS Data Sharing Service

Compliance, Storage, & Dissemination

Share Data

Research Community

QUALIFIED INVESTIGATORS

ADSP WORKGROUPS

PROGRAM INITIATIVES

ADSP-PHC Teams

Fluid Biomarker Harmonization



Carlos Cruchaga, PhD
Washington University

Coordinating Center



Timothy Hohman, PhD
Vanderbilt University
Medical Center
Contact-PI



Michael Cuccaro, PhD
University of Miami
MPI

Diffusion MRI Harmonization



Bennett Landman, PhD
Vanderbilt University

Cognitive Harmonization



Paul Crane, MD, MPH
University of Washington



Jesse Mez, MD, MS
Boston University

Storage & Informatics



Arthur Toga, PhD
University of Southern California
MPI

CHARGE Coordination



Mohamad Habes, PhD
University of Texas Health
San Antonio

Structural MRI Harmonization



Shannon Risacher, PhD
Indiana University



Christos Davatzikos,
PhD
University of
Pennsylvania

Vascular Harmonization



Adam Brickman, PhD
Columbia University



Richard Mayeux, MD,
MSc
Columbia University

Integration & Analytics



Paul Thompson, PhD
University of Southern
California



Andrew Saykin, PsyD
Indiana University

Neuropathology Harmonization



Thomas Montine, MD,
PhD
Stanford University



Gary Beecham, PhD
University of Miami

PET Harmonization




Elizabeth Mormino, PhD
Stanford University




Duygu Tosun, PhD
University of California
San Francisco

Amyloid PET Harmonization




Z-Score using Mean and Standa




Structural T1 MRI Harmonization

Age Differences in Hippocampal Volume before Harmonization



Age Differences in Hippocampal Volume After Harmonization



Legend: ADNI-2 AIBL BLSA-3T CARDIA PAC-WASH SHIP UKBIOBANK

Data Harmonized in Year 2

Cohort	Autopsy	Vascular Risk Factors	Cognition	Fluid Biomarker	Diffusion Tensor Imaging (DTI)	Fluid Attenuated Inversion Recovery (FLAIR)	Magnetic Resonance Imaging (MRI) Freesurfer	Magnetic Resonance Imaging (MRI) MUSE	Positron Emission Tomography (PET) Amyloid	Positron Emission Tomography (PET) Tau
TOTAL	23,020	57,083	83,548	3,047	2,830	10,020	7,679	10,590	7,602	1,836
A4	0	0	6,595	0	0	1,198	0	0	4,486	447
ACT	532	0	5,546	0	0	0	0	0	0	0
ADNI	0	1,577	3,539	1,249	1,198	7,054	2,560	2,592	1,803	944
EFIGA	0	5,965	6,903	0	0	0	0	0	0	0
Knight ADRC	0	0	2,477	64	0	0	0	0	0	0
NACC	19,899	41,172	41,538	2,094	646	0	3,690	5,004	920	102
NIA-AD FBS	570	405	4,564	0	0	0	0	0	0	0
ROS/MAP/ MARS	2,019	4,500	4,550	0	643	0	0	1,183	0	0
WHICAP	0	1,830	6,257	0	0	1,768	929	1,197	0	0
WRAP	0	1,634	1,579	0	343	0	500	614	393	343

Freeze 2: Harmonized Data with Sequence Data

Cohort	Autopsy	Vascular Risk Factors	Cognition	Fluid Biomarker	Diffusion Tensor Imaging (DTI)	Fluid Attenuated Inversion Recovery (FLAIR)	Magnetic Resonance Imaging (MRI) Freesurfer	Magnetic Resonance Imaging (MRI) MUSE	Positron Emission Tomography (PET) Amyloid	Positron Emission Tomography (PET) Tau
TOTAL	6,795	15,565	25,278	2,034	967	3,278	3,630	4,329	4,955	912
A4	0	0	3,373	0	0	963	0	0	3,378	345
ACT	532	0	1,337	0	0	0	0	0	0	0
ADNI	0	876	1,546	1,165	502	1,009	1,558	1,564	1,128	321
EFIGA	0	1,183	1,248	0	0	0	0	0	0	0
Knight ADRC	0	0	837	64	0	0	0	0	0	0
NACC	4,908	10,872	10,615	805	203	0	1,056	1,462	213	26
NIA-AD FBS	262	28	553	0	0	0	0	0	0	0
ROS/MAP/ MARS	1,093	1,254	1,271	0	77	0	0	165	0	0
WHICAP	0	604	3,786	0	0	1,306	712	770	0	0
WRAP	0	748	712	0	185	0	304	368	236	220

<https://dss.niagads.org/>
December 2023


Sample sizes reflect individuals with ADSP sequencing data, with exception to A4, which will have sequenced data available in R5.



Exploring the Genetic Architecture of AD Leveraging Endophenotypes

Explorations into the Genetic Architecture of Memory

GWAS of Memory Performance



Archer et al., Alzheimer's & Dementia, In Press

26,633 participants over 129,201 longitudinal visits


Sex Differences in APOE

	Memory Performance	Executive Functioning	Language Performance
APOE-ε4	↑ F M	F M	↑ F M
APOE-ε2	F M	F M	F M

Walters et al., JAMA Neurology, 2023

32,427 Participants including 4,453 non-Hispanic Black

Sex-Specific GWAS of Memory




Eissman et al., Alzheimer's & Dementia, In Press

26,633 participants over 129,201 longitudinal visits

Sex-Specific Genetic Drivers of Language



Jackie Eissman
PhD




$N_{males} = 15,493$


$N_{females} = 20,681$

Sex Differences in VRK2 Association with Language

Males



Females





Integrative Analysis for More Precise Phenotypes


Integrative Analytics

Applying Advanced Algorithms to Increase Statistical Power


Age of Onset of A β + Calculation



Mixed Effects Sigmoidal Model



Resistance and Resilience







Jared Phillips
Graduate Student

Approximating Resilience w/o Path Measures


Silver Model

Mixed Effects Model Predictors:
Age, Sex, Race, APOE, Baseline Performance,
Time and 3-way Interactions
Variance explained = 26%
Sample Size (3+ Visits) = **20,339**




Gold Model

Mixed Effects Model Predictors:
Age, Sex, Race, APOE, Pathology, Baseline
Performance, Time
and 3-way Interactions
Variance explained = 55%
Sample Size: **5,107**





Gold Standard Results




Silver Standard Results

New Resilience and Resistance Loci




Deep Molecular Characterization of High Quality Candidates

Drug Discovery Framework in the Computational Neurogenomics Team




Vascular Endothelial Growth Factor


CSF VEGF Levels Associated with Slower Future Cognitive Decline





(Hohman, Bell, & Jefferson, *JAMA Neurology*, 2015)




Blood Vessel Overgrowth on Cell



© LUNevity Foundation





Ruiz et al., 2009. *Physiol Rev*.



Emily Mahoney


VEGF Transcript Association in the Brain


Brain Expression of Vascular Endothelial Growth Factor



Replication in Independent Dataset



Differences in temporal cortex gene expression between AD participants and controls







Mabel Seto, PhD

FLT1 and VEGFB Robustly Relate to AD outcomes



Confirming snRNA Associations in Prefrontal Cortex



Sample size: 424

Post-translational Modifications

The FASEB Journal express article 10.1096/fj.03-0767fje. Published online March 4, 2004.

The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1)

Satsuki Kobayashi,^{*,†} Asako Sawano,^{*} Yoshihisa Nojima,[†] Masabumi Shibuya,^{*} and Yoshiro Maru^{*,‡}

PLOS ONE

OPEN ACCESS PEER-REVIEWED


RESEARCH ARTICLE

N-Terminal Cleavage and Release of the Ectodomain of Flt1 Is Mediated via ADAM10 and ADAM 17 and Regulated by VEGFR2 and the Flt1 Intracellular Domain

Nandita S. Raikwar, Kang Z. Liu, Christie P. Thomas

Published: November 11, 2014 • <https://doi.org/10.1371/journal.pone.0112794>

FLT1 Ubiquitination is Upregulated in AD



FLT1 is a Druggable Target

Druggability of FLT1

AMP-AD pharmaceutical partners scored the tractability of targets using publicly-available resources and have generated ratings of small-molecule druggability, therapeutic antibody feasibility, and safety.

[Learn more about the analysis](#)

Small Molecule Modality	1	Small molecule druggable: Protein with a small molecule ligand identified from ChEMBL, meeting TCRD activity criteria.	+
Antibody Modality	1	Secreted protein. Highly accessible to antibody-based therapies.	+
Safety	1	Clinical data, evidence of tolerable safety profile in desired modality; target has a drug in phase IV in the appropriate modality, with good safety profile.	+




TREAT-AD

TaRget Enablement to Accelerate
Therapy Development for AD




Agora


Drug Discovery Framework in the Computational Neurogenomics Team




Collaborations to Move Targets Forward




Exploring Sex Differences with Single Cell Resolution




Striking Sex Differences in Immune Cells in AD




CD99 male_normal signaling pathway network



CD99 male_AD signaling pathway network



CD99 female_normal signaling pathway network



Yiyang Wu, MD, PhD

Acknowledgements



- **Derek Archer, PhD**
- Mary Ellen Koran, MD, PhD
- Annah Scalfani, PhD
- Mabel Seto, PhD
- Rebecca Winfree, PhD
- Shannon Mercado, BA
- Skylar Walters, MA
- Alaina Durant, BA
- Jared Phillips, ABD
- **Logan Dumitrescu, PhD**
- Vaibhav Janve, PhD
- Michelle Clifton, MA
- Yiyang Wu, MD, PhD
- Jackie Eissman, PhD
- Tonnar Castellano, MA
- Alex Contreas, BS
- Julia Libby, BS
- Emily Mahoney, BA

Vanderbilt Memory & Alzheimer's Center

- Angela Jefferson, PhD
- Katie Gifford, PsyD
- Matthew Schrag, MD
- **Bennett Landman, PhD**

Vanderbilt Genetics Institute

- Nancy Cox, PhD
- Lea Davis, PhD
- Douglas Ruderfer, PhD

Rush University Medical Center

- David Bennett, MD
- Julie Schneider, MD

National Institute on Aging

- Susan Resnick, PhD
- Murat Bilgel, PhD

Jackson Laboratory

- Catherine Kaczorowski, PhD
- Gareth Howell, PhD
- Kristen O'Connell, PhD

University of Wisconsin

- Sterling Johnson, PhD
- Corinne Engelman, PhD
- Qiognshi Lu, PhD
- Yuetiva Deming, PhD

Columbia University

- Richard Mayeux, MD
- Neha Raghavan, PhD
- Badri Vadarajan, PhD
- Adam Brickman, PhD
- Jennifer Manly, PhD

University of Miami

- **Michael Cuccaro, PhD**
- Margaret Pericak-Vance, PhD
- Brian Kunkle, PhD
- Gary Beecham, PhD

Stanford University

- Eden Martin, PhD
- Elizabeth Mormino, PhD
- Thomas Montine, MD

University of Pennsylvania

- Gerard Schellenberg, PhD
- Li San Wang, PhD
- Amanda Kuzma, MS
- **Christos Davatzikos, PhD**

University of Southern California

- Paul Thompson, PhD
- Duygu Tosun, PhD
- Arthur Toga, PhD

Harvard Medical School

- Rachel Buckley, PhD
- Jonathan Haines, PhD
- William Bush, PhD

Case Western University

- Jesse Mez, MD

Boston University

- Jesse Mez, MD

Johns Hopkins University

- Marilyn Albert, PhD
- Alden Gross, PhD

University of Washington

- **Paul Crane, MD**
- **Joey Mukherjee, PhD**
- **Emily Trittschuh, PhD**
- **Walter Kukull, PhD**
- **Seo-Eun Choi, PhD**
- **Brandon Klinedinst, PhD, MS**
- **Michael Lee, PhD**
- **Phoebe Scollard, MA**
- **Eric Larson, MD**

Pacific Northwest National Lab

- Vlad Petyuk, PhD

Washington University in St. Louis

- Carlos Cruchaga, PhD
- Oscar Harari, PhD
- Bruno Benitez, MD

Indiana University

- Andy Saykin, PsyD
- Shannon Risascher, PhD

UTHSA

- Mohamad Habes, PhD
- Sudha Seshadri, PhD

Funding: U24-AG074855, R01-AG061518, R01-AG061518, P20-AG068082, U01-AG068057, R21-AG059941, K01-AG049164, K12-HD043483, HHSN311201600276P, RF1-AG059869